サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1574655

がん抗体薬物複合体の世界市場：市場規模、薬剤承認、薬価、販売、臨床試験に関する洞察（2030年）

Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030

出版日
ページ情報
英文 1300 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

がん抗体薬物複合体の世界市場：市場規模、薬剤承認、薬価、販売、臨床試験に関する洞察（2030年）
出版日: 2024年10月01日
発行: KuicK Research
ページ情報: 英文 1300 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体薬物複合体（ADC）は、モノクローナル抗体の特異性と細胞毒性薬剤の効能を併せ持つ、がん治療において革新的な治療薬として登場しました。この革新的な治療法は、安定したリンカーを介して細胞毒性薬剤と結合した抗体から構成されており、周囲の健康な組織へのダメージを最小限に抑えながら、がん細胞に標的を絞って送達することができます。抗体薬物複合体の急速な進化は、その臨床的・商業的成功を反映しており、現在、さまざまな市場で16製品が承認され、販売高は2023年に100億米ドル、2024年の最初の6ヵ月で70億米ドルを突破しています。この成長は、抗体薬物複合体がより広範ながん治療薬市場において商業的に実行可能なセグメントであることを浮き彫りにし、より効果的で安全な候補化合物の創製に向けた研究開発の活発化を促しています。

2024年10月現在、世界の規制当局は16種類の抗体薬物複合体を承認しており、現在13種類がさまざまながん種に対して臨床使用可能です。このうち、代表的なものにはパドセブ、カドサイラ、エンヘルツがあり、2023年の抗体薬物複合体売上高全体の約60%を占めています。Enhertuは複数のHER2陽性固形がんの治療に適応がありますが、PadcevとKadcylaはそれぞれ膀胱がんと乳がんの治療にのみ承認されています。これらの製品タイプは、治療の可能性だけでなく、さまざまながん種を管理するADCの有効性に対する市場の信頼が高まっていることを示しています。

世界のがん抗体薬物複合体市場は競合情勢に特徴があり、固形がんや血液悪性腫瘍を含む複数のがんを標的とした開発が活発に行われています。しかし、その中でも肺がんは現在最も広範な開発活動が行われており、CAB-AXL-ADC、TQB2102、MYTX-011を含む60以上の候補が臨床試験段階にあり、Enhertuが1つ臨床での使用が承認されています。これは、依然として世界のがん死亡の主要原因のひとつである肺がんにおいて、アンメットメディカルニーズの高い治療薬への戦略的転換を反映したものです。抗体薬物複合体は、より効果的で毒性の低い治療選択肢を提供する可能性があり、この治療領域では特に魅力的です。

特徴 詳細
主要セグメント 用途：がんタイプ別、地域別、技術プラットフォーム
対象となる適応症 対象疾患：肺がん、乳がん、子宮頸がん、膵臓がん、食道がん、その他
主要対象国 米国、中国、韓国、カナダ、インドなど
対象薬剤 Enhertu、Adcetris、Polivy、Kadcylaなど
レポート対象範囲 作用機序、ADC世代、パイプラインと承認薬の洞察、販売洞察、現在の動向、将来の機会、市場促進要因・課題
対象企業 Biocytogen、Merck、AstraZeneca、Pfizer、Daiichi Sankyo、ADC Therapeuticsなど

当レポートは、世界のがん抗体薬物複合体市場について調査し、市場の概要とともに、薬剤動向、臨床試験動向、地域別動向、および市場に参入する企業の競合情勢などを提供しています。

目次

第1章 抗体薬物複合体のイントロダクション

  • 概要
  • 抗体薬物複合体のメカニズム

第2章 がん標的治療としての抗体薬物複合体

  • がんにおける抗体薬物複合体の応用
  • 抗体薬物複合体の利点
  • 抗体薬物複合体と従来の治療法の比較

第3章 抗体薬物複合体の世代

  • 抗体薬物複合体- 進化
  • 次世代抗体薬物複合体の展望

第4章 市販の承認済み抗体薬物複合体、ブランド名、会社、適応症別

第5章 世界のがん抗体薬物複合体の臨床試験の概要

  • 相別
  • 適応症別
  • 企業別
  • 患者セグメント別
  • 国別

第6章 世界のがん抗体薬物複合体市場の見通し

第7章 世界のがん抗体薬物複合体の調査と市場動向、地域別

  • 米国
  • 中国
  • 欧州
  • 韓国
  • オーストラリア
  • 英国
  • カナダ
  • 日本
  • インド
  • ラテンアメリカ

第8章 世界のがん抗体薬物複合体市場の動向と発展、適応症別

  • 肺がん
  • 乳がん
  • 白血病
  • 卵巣がん
  • 消化器がん
  • リンパ腫
  • 泌尿生殖器がん
  • 子宮頸がん
  • 頭頸部がん
  • 脳腫瘍
  • 前立腺がん
  • 膵臓がん
  • 皮膚がん
  • 食道がん

第9章 がん抗体薬物複合体開発プラットフォーム、企業別

第10章 承認済みがん抗体薬物複合体- 特許、投与量、価格分析

  • ミロターグ
  • アドセトリス
  • カドシラ
  • ベスポンサ
  • ルモキシティ（2023年市場撤退）
  • ポリヴィ
  • パドチェフ
  • エンヘルトゥ
  • トロデルヴィ
  • ブレンレップ（2023年に一部市場撤退）
  • ジンロンタ
  • ティヴダク
  • エラヘレ
  • ウジヴィラ
  • アカラックス
  • アイディクシ

第11章 承認済みがん抗体薬物複合体- 販売の洞察と2028年の予測

第12章 企業、国、適応症、相別の世界のがん抗体薬物複合体臨床試験の洞察

  • 研究
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 事前登録

第13章 上市済みがん抗体薬物複合体の企業、国、適応症別の臨床的洞察

第14章 がん抗体薬物複合体の併用療法

第15章 世界のがん抗体薬物複合体市場概要

第16章 競合情勢

  • Biocytogen
  • Bristol Myers Squibb
  • Eli Lilly
  • Innovent Biologics
  • Merck
  • Pfizer
  • Affinity Biopharma
  • Biokin
  • Synaffix
  • ADC Therapeutics
  • AstraZeneca
  • Daiichi Sankyo
  • Duality Biologics
  • Immunogen
  • LigaChem Biosciences
図表

List of Figures

  • Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
  • Figure 2-1: Advantages of Antibody Drug Conjugates
  • Figure 3-1: Antibody-Drug Conjugates - Approval by Generation
  • Figure 3-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
  • Figure 5-1: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Phase, 2024 Till 2030
  • Figure 5-2: Global- Cancer Antibody Drug Conjugates In Clinical Trials By Indication, 2024 Till 2030
  • Figure 5-3: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Company, 2024 Till 2030
  • Figure 5-4: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Patient Segment, 2024 Till 2030
  • Figure 5-5: Global - Cancer Antibody Drug Conjugates In Clinical Pipeline By Country, 2024 Till 2030
  • Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2024
  • Figure 6-2: Global -Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), Q1'2024
  • Figure 6-3: Global - Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), Q2'2024
  • Figure 6-4: Global - Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), H1'2024
  • Figure 6-5: Global - Cancer Antibody Drug Conjugates Market Share by Drugs (%), H1'2024
  • Figure 6-6: Global - Cancer Antibody Drug Conjugates Market (US$ Million), Q1 & Q2'2024
  • Figure 6-7: Global - Cancer Antibody Drug Conjugates Market by Drug (US$ Million), 2023
  • Figure 6-8: Global - Cancer Antibody Drug Conjugates Market Share by Drugs (%), 2023
  • Figure 6-9: Global - Cancer Antibody Drug Conjugates Market (US$ Million), Q1-Q4'2023
  • Figure 6-10: Global - Cancer Antibody Drug Conjugates Market Forecast (US$ Billion), 2024 - 2030
  • Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
  • Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), October'2024
  • Figure 8-1: Datopotamab Deruxtecan Phase 3 (NCT04656652) Study - Initiation & Completion Year
  • Figure 8-2: Luveltamab tazevibulin Phase 2 (NCT06555263) Study - Initiation & Completion Year
  • Figure 8-3: Ifinatamab Deruxtecan Phase 3 (NCT06203210) Study - Initiation & Completion Year
  • Figure 8-4: Sigvotatug Vedotin Phase 3 (NCT06012435) Study - Initiation & Completion Year
  • Figure 8-5: Sacituzumab Tirumotecan Phase 3 (NCT06074588) Study - Initiation & Completion Year
  • Figure 8-6: Datopotamab deruxtecan Phase 3 (NCT05104866) Study - Initiation & Completion Year
  • Figure 8-7: Datopotamab deruxtecan Phase 3 (NCT06112379) Study - Initiation & Completion Year
  • Figure 8-8: TQB2102 Phase 3 (NCT06561607) Study - Initiation & Completion Year
  • Figure 8-9: ORM-5029 Phase 1 (NCT05511844) Study - Initiation & Completion Year
  • Figure 8-10: BMS-986497 Phase 1 (NCT06419634) Study - Initiation & Completion Year
  • Figure 8-11: JBH492 Phase 1 (NCT04240704) Study - Initiation & Completion Year
  • Figure 8-12: Rinatabart sesutecan Phase 3 (NCT06619236) Study - Initiation & Completion Year
  • Figure 8-13: Luveltamab tazevibulin Phase 2/3 (NCT05870748) Study - Initiation & Completion Year
  • Figure 8-14: Raludotatug Deruxtecan (R-DXd) Phase 2/3 (NCT06161025) Study - Initiation & Completion Year
  • Figure 8-15: AZD5335 Phase 1/2 (NCT05797168) Study - Initiation & Completion Year
  • Figure 8-16: Dato-DXd Phase 2 (NCT05489211) Study - Initiation & Completion Year
  • Figure 8-17: IKS014 Phase 1 (NCT05872295) Study - Initiation & Completion Year
  • Figure 8-18: AZD0901 Phase 2 (NCT06219941) Study - Initiation & Completion Year
  • Figure 8-19: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation & Completion Year
  • Figure 8-20: Loncastuximab tesirine Phase 2 (NCT05453396) Study - Initiation & Completion Year
  • Figure 8-21: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
  • Figure 8-22: Zilovertamab vedotin Phase 1/2 (NCT06395103) Study - Initiation & Completion Year
  • Figure 8-23: Padcev Phase 2 (NCT05775471) Study - Initiation & Completion Year
  • Figure 8-24: Trodelvy Phase 2 (NCT05581589) Study - Initiation & Completion Year
  • Figure 8-25: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation & Completion Year
  • Figure 8-26: 9MW2821 Phase 3 (NCT06196736) Study - Initiation & Completion Year
  • Figure 8-27: Trodelvy Phase 2 (NCT05838521) Study - Initiation & Completion Year
  • Figure 8-28: Enhertu Phase 2 (NCT04482309) Study - Initiation & Completion Year
  • Figure 8-29: 9MW2821 Phase 1/2 (NCT05216965) Study - Initiation & Completion Year
  • Figure 8-30: Aidixi Phase 2 (NCT06003231) Study - Initiation & Completion Year
  • Figure 8-31: Padcev Phase 2 (NCT04225117) Study - Initiation & Completion Year
  • Figure 8-32: Ozuriftamab vedotin Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
  • Figure 8-33: Panitumumab-IRDye800 Phase 1/2 (NCT03510208) Study - Initiation & Completion Year
  • Figure 8-34: Patritumab deruxtecan (HER3-DXd) Phase 2 (NCT05865990) Study - Initiation & Completion Year
  • Figure 8-35: Trodelvy Phase 2 (NCT03725761) Study - Initiation & Completion Year
  • Figure 8-36: HS-20093 Phase 2 (NCT06001255) Study - Initiation & Completion Year
  • Figure 8-37: FOR46 Phase 1b/2 (NCT05011188) Study - Initiation & Completion Year
  • Figure 8-38: ARX517 Phase 1 (NCT04662580) Study - Initiation & Completion Year
  • Figure 8-39: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
  • Figure 8-40: SOT102 Phase 1/2 (NCT05525286) Study - Initiation & Completion Year
  • Figure 8-41: TORL-2-307 Phase 1 (NCT05156866) Study - Initiation & Completion Year
  • Figure 8-42: EBC-129 Phase 1 (NCT05701527) Study - Initiation & Completion Year
  • Figure 8-43: Panitumumab-IRDye800 Phase 1/2 (NCT03384238) Study - Initiation & Completion Year
  • Figure 8-44: Ozuriftamab vedotin Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
  • Figure 8-45: Vobramitamab duocarmazine (MGC018) Phase 1 (NCT05293496) Study - Initiation & Completion Year
  • Figure 8-46: AMT253 Phase 1/2 (NCT06209580) Study - Initiation & Completion Year
  • Figure 8-47: Zirconium Zr 89 Crefmirlimab Berdoxam Phase 2 (NCT05013099) Study - Initiation & Completion Year
  • Figure 8-48: Enhertu Phase 2 (NCT05480384) Study - Initiation & Completion Year
  • Figure 8-49: HS-20093 Phase 2 (NCT06112704) Study - Initiation & Completion Year
  • Figure 8-50: DP303c Phase 1/2 (NCT06577376) Study - Initiation & Completion Year
  • Figure 9-1: Proprietary ADC Technology - Seagen
  • Figure 9-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
  • Figure 9-3: TRAAC- Tallac Therapeutics
  • Figure 9-4: ATAC- Heidelberg Pharma
  • Figure 9-5: Tub-tag(R) & P5 - Tubulis
  • Figure 10-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
  • Figure 10-2: Mylotarg - Approval Year by Region
  • Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), October'2024
  • Figure 10-4: Mylotarg - Cost of 5 mg Supply in UK (US$), October'2024
  • Figure 10-5: US - Adcetris FDA Approval Year by Indication
  • Figure 10-6: Adcetris - Approval Year by Region
  • Figure 10-7: Japan - Adcetris PMDA Approval Year by Indication
  • Figure 10-8: US - Adcetris Orphan Drug Designation Approval Year by Indication
  • Figure 10-9: Adcetris - Patent Expiration by Region
  • Figure 10-10: Adcetris - Cost of 50 mg Supply in US & UK (US$), October'2024
  • Figure 10-11: US - Kadcyla FDA Approval Year by Indication
  • Figure 10-12: Kadcyla - Approval Year by Region
  • Figure 10-13: US - Kadcyla FDA Approval & Patent Expiration Year
  • Figure 10-14: Kadcyla - Cost of Supply in US, Europe & UK (US$), October'2024
  • Figure 10-15: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
  • Figure 10-16: Besponsa - Approval Year by Region
  • Figure 10-17: Besponsa - Cost of 0.9 mg Supply in US, October'2024
  • Figure 10-18: Besponsa - Cost of 1 mg Supply in Europe & UK (US$), October'2024
  • Figure 10-19: Lumoxiti - Orphan Designation Years
  • Figure 10-20: Lumoxiti - Patent Expiry Years
  • Figure 10-21: Lumoxiti - Cost of 1 mg Supply in US & Europe (US$), October'2024
  • Figure 10-22: Polivy - Approval Year by Region
  • Figure 10-23: Polivy - Orphan Drug Designation Approval Year by Region
  • Figure 10-24: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
  • Figure 10-25: Polivy - Cost of 140 mg Supply in Europe (US$), October'2024
  • Figure 10-26: Polivy - Cost of 30 & 140 mg Supply in US & UK (US$), October'2024
  • Figure 10-27: Padcev - Approval Year by Region
  • Figure 10-28: US - Padcev FDA Approval & Patent Expiration Year
  • Figure 10-29: Padcev - Cost of 20 & 30 mg Supply In US & Europe (US$), October'2024
  • Figure 10-30: Enhertu - Approval Year by Region
  • Figure 10-31: US - Polivy FDA Approval Year by Indication
  • Figure 10-32: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
  • Figure 10-33: Enhertu - Cost of 100 mg Supply In US, Europe & UK (US$), October'2024
  • Figure 10-34: US - Trodelvy FDA Approval by Indication
  • Figure 10-35: Trodelvy - Approval Year by Region
  • Figure 10-36: Trodelvy - Patent Expiration by Region
  • Figure 10-37: Trodelvy - Cost of 180 mg Supply In US & UK (US$), October'2024
  • Figure 10-38: Trodelvy - Cost of 180 & 200 mg Supply In Europe (US$), October'2024
  • Figure 10-39: Blenrep - FDA & EMA Orphan Drug Designations
  • Figure 10-40: Blenrep - FDA & EMA Approval
  • Figure 10-41: Zynlonta - FDA & EMA Approval Years
  • Figure 10-42: Zynlonta - FDA & EMA Orphan Drug Designation Years
  • Figure 10-43: Zynlonta - Cost of 10 mg Supply In US, Europe & UK (US$), October'2024
  • Figure 10-44: Tivdak - Cost of 40 mg Supply In US & Europe (US$), October'2024
  • Figure 10-45: Elahere - Cost of Unit & Supply In US (US$), October'2024
  • Figure 10-46: Ujvira - Cost of 100 mg & 160 mg Supply (US$), October'2024
  • Figure 10-47: Akalux - Sakigake Designation & PMDA Approval Year
  • Figure 10-48: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
  • Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2024
  • Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2024
  • Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2024
  • Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2024
  • Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-12: Polivy - Global Sales By Region (%), H1'2024
  • Figure 11-13: Polivy - US Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-14: Polivy - US Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-15: Polivy - Europe Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-16: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-17: Polivy - Japan Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-18: Polivy - Global Sales By Region (US$ Million), Q1-Q4'2023
  • Figure 11-19: Polivy - Global Sales By Region (%), 2023
  • Figure 11-20: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-21: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-22: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-24: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-25: Kadcyla - Global Sales Values (US$ Million), 2020-2024
  • Figure 11-26: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-27: Kadcyla - Global Sales By Region (%), H1'2024
  • Figure 11-28: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-29: Kadcyla - Global Sales By Region (US$ Million), Q1-Q4'2023
  • Figure 11-30: Kadcyla - Global Sales By Region (%), 2023
  • Figure 11-31: Kadcyla - US Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-32: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-33: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-34: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-35: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-36: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-37: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-38: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-39: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-40: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2024
  • Figure 11-41: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-42: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2023
  • Figure 11-43: Besponsa - Global Annual Sales (US$ Million), 2020-2023
  • Figure 11-44: Besponsa - Global Sales by Region (US$ Million), 2023
  • Figure 11-45: Besponsa - Quarterly Sales by Region (%), 2023
  • Figure 11-46: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-47: Besponsa - US Annual Sales (US$ Million), 2020-2023
  • Figure 11-48: Besponsa - Europe Quarterly Sales (US$ Million), 2022
  • Figure 11-49: Besponsa - ROW Quarterly Sales (US$ Million), 2022
  • Figure 11-50: Enhertu - Global Annual Sales (US$ Million), 2020-2024
  • Figure 11-51: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2024
  • Figure 11-52: Enhertu - Global Quarterly Sales (US$ Million), 2022
  • Figure 11-53: Trodelvy - Global Annual Sales (US$ Million), 2020-2024
  • Figure 11-54: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-55: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-56: Trodelvy - Annual Sales By Region (US$ Million), 2023
  • Figure 11-57: Trodelvy - Annual Sales By Region (%), 2023
  • Figure 11-58: Trodelvy - US Annual Sales (US$ Million), 2020-2024
  • Figure 11-59: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-60: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-61: Trodelvy - Europe Annual Sales (US$ Million), 2020-2024
  • Figure 11-62: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-63: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-64: Trodelvy - ROW Annual Sales (US$ Million), 2020-2024
  • Figure 11-65: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-66: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-67: Zynlonta - Global Annual Sales (US$ Million), 2021-2024
  • Figure 11-68: Zynlonta - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-69: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-70: Elahere - Global Annual Sales (US$ Million), 2022-2024
  • Figure 11-71: Elahere - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
  • Figure 11-72: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 11-73: Blenrep - Global Annual Sales (US$ Million), 2020-2023
  • Figure 11-74: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4'2023
  • Figure 14-1: Antibody Drug Conjugate Combinations in Studies
  • Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables

  • Table 3-1: First Generation Antibody Drug Conjugates - Examples
  • Table 3-2: Second Generation Antibody Drug Conjugates - Examples
  • Table 3-3: Third Generation Antibody Drug Conjugates - Examples
  • Table 3-4: Fourth Generation Antibody Drug Conjugates - Examples
  • Table 4-1: Approved Antibody Drug Conjugates
  • Table 6-1: Cancer Antibody Drug Conjugates Market - Recent Acquisition Deals
  • Table 6-2: Cancer Antibody Drug Conjugates - Recent Collaborations
  • Table 6-3: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
  • Table 6-4: Cancer Antibody Drug Conjugates - Companies Announcing Plans for Manufacturing Facilities
  • Table 6-5: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
  • Table 6-6: Cancer Antibody Drug Conjugates - Recent IND Clearances
  • Table 7-1: US - Approved Cancer Antibody Drug Conjugates, October'2024
  • Table 7-2: US - Antibody Drug Conjugate Under FDA Review, October'2024
  • Table 7-3: China - Approved Antibody Drug Conjugates, October'2024
  • Table 7-4: EU - Approved Cancer Antibody Drug Conjugates, October'2024
  • Table 7-5: Australia - Approved Cancer Antibody Drug Conjugates, October'2024
  • Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, October'2024
  • Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, October'2024
  • Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates
  • Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates
  • Table 8-3: Leukemia - Approved Antibody Drug Conjugates
  • Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
  • Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
  • Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
  • Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
  • Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
  • Table 8-9: Head & Neck Cancer - Approved Antibody Drug Conjugates
  • Table 10-1: Adcetris - Recommended Dosage
  • Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials
目次

"Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" Report Finding and Inclusions:

  • Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
  • Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
  • Approved Cancer Antibody Drug Conjugates: 16 Drugs
  • Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage & Price Analysis
  • Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
  • Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
  • Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication
FeaturesDetails
Key Segments:Application by Cancer Type, By Region, Technology Platforms
Indications Covered:Lung Cancer, Breast Cancer, Cervical Cancer, Pancreatic Cancer, Pancreatic Cancer, Esophageal Cancer, among others
Key Countries Covered:US, China, South Korea, Canada, India, among others
Drugs Covered:Enhertu, Adcetris, Polivy, Kadcyla, among others
Report Coverage:Mechanism of Action, ADC Generations, Pipeline & Approved Drugs Insight, Sales Insight, Current Trends, Future Opportunities, Market Drivers & Challenges
Companies Covered:Biocytogen, Merck, AstraZeneca, Pfizer, Daiichi Sankyo, ADC Therapeutics, among others

Antibody drug conjugates (ADCs) have emerged as a transformative class of therapeutics in the cancer treatment landscape, integrating the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These innovative therapies consist of an antibody linked to a cytotoxic agent through a stable linker, allowing targeted delivery to cancer cells while minimizing damage to surrounding healthy tissues. The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.

As of October 2024, regulatory authorities around the world have approved 16 antibody drug conjugates, with 13 currently available for clinical use for different cancer types. Among these, prominent examples include Padcev, Kadcyla, and Enhertu, which collectively accounted for approximately 60% of the total antibody drug conjugates sales in 2023. While Enhertu is indicated for the treatment of several HER2-positive solid cancers, Padcev and Kadcyla are solely approved for the treatment of bladder cancer and breast cancer, respectively. The commercialization of these products demonstrates not only their therapeutic potential but also the market's growing confidence in the effectiveness of ADCs in managing various cancer types.

Global cancer antibody drug conjugates market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancers, including both solid tumors and hematological malignancies. However, out of all these, lung cancer is currently witnessing the most extensive development activity, with over 60 candidates in clinical trials, including CAB-AXL-ADC, TQB2102, and MYTX-011, and one Enhertu, approved for use in clinical setting. This reflects a strategic shift towards addressing the high-unmet medical need in lung cancer, which remains one of the leading causes of cancer mortality worldwide. The potential for antibody drug conjugates to provide more effective and less toxic treatment options makes them particularly attractive in this therapeutic area.

In contrast, however, breast cancer has experienced the highest number of antibody drug conjugates approvals to date, with four approved candidates, contributing significantly to the market's commercial success. Two key players in this domain are the aforementioned Kadcyla and Enhertu, both of which have demonstrated remarkable efficacy and have achieved significant sales milestones. The promising pipeline also includes AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan, a TROP2-directed antibody drug conjugate that is currently under review for its use in breast cancer treatment. This continued investment in research and development underscores the critical role antibody drug conjugates play in advancing cancer care.

Regionally, the cancer antibody drug conjugates market is primarily led by the US and China, two of the largest and most dynamic pharmaceutical markets globally. In the US, robust healthcare infrastructure, high R&D expenditure, and a favorable regulatory environment foster innovation and accelerate the approval process for new therapies. Additionally, the presence of major pharmaceutical companies, such as Regeneron, Gilead, Merck and Pfizer, bolsters the competitive landscape, enabling rapid development and commercialization of antibody drug conjugates.

In China, the growing demand for advanced cancer treatments, coupled with increasing government support for biotechnology and pharmaceutical research, has catalyzed significant growth in the antibody drug conjugates sector. Local players like Mabwell, Miracogen, Chia Tai Tianqing Pharmaceutical, Hansoh BioMedical, Sichuan Baili Pharmaceuticals, Biocytogen and Affinity Biopharma are emerging as significant contributors to the market, developing novel Antibody drug conjugates tailored to the specific needs of the Chinese patient population, and out licensing promising candidates to their international counterparts through license agreements.

The global market for cancer antibody drug conjugates represents a dynamic and rapidly evolving segment of the cancer therapeutics landscape. With ongoing clinical trials, innovative research, and increasing regulatory support, antibody drug conjugates are poised to play an increasingly pivotal role in cancer treatment. As efforts continue to address existing challenges and expand the range of approved indications, the future of antibody drug conjugates appears promising, offering hope to patients worldwide in the fight against cancer. The collaborative efforts among pharmaceutical companies, regulatory bodies, and research institutions will be crucial in shaping the next wave of advancements in this exciting therapeutic field.

Table of Contents

1. Introduction To Antibody Drug Conjugates

  • 1.1 Overview
  • 1.2 Mechanism of Antibody Drug Conjugates

2. Antibody Drug Conjugates As Cancer Targeted Therapy

  • 2.1 Applications of Antibody Drug Conjugates in Cancer
  • 2.2 Advantages of Antibody Drug Conjugates
  • 2.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

3. Generations of Antibody Drug Conjugates

  • 3.1 Antibody Drug Conjugates - Evolution
  • 3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

5. Global Cancer Antibody Drug Conjugates Clinical Trials Overview

  • 5.1 By Phase
  • 5.2 By Indication
  • 5.3 By Company
  • 5.4 By Patient Segment
  • 5.5 By Country

6. Global Cancer Antibody Drug Conjugates Market Outlook

  • 6.1 Current Market Scenario
  • 6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

  • 7.1 US
  • 7.2 China
  • 7.3 Europe
  • 7.4 South Korea
  • 7.5 Australia
  • 7.6 UK
  • 7.7 Canada
  • 7.8 Japan
  • 7.9 India
  • 7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

  • 8.1 Lung Cancer
  • 8.2 Breast cancer
  • 8.3 Leukemia
  • 8.4 Ovarian Cancer
  • 8.5 Gastrointestinal Cancer
  • 8.6 Lymphoma
  • 8.7 Urogenital Cancer
  • 8.8 Cervical Cancer
  • 8.9 Head & Neck Cancer
  • 8.10 Brain Cancer
  • 8.11 Prostate cancer
  • 8.12 Pancreatic Cancer
  • 8.13 Skin cancer
  • 8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

  • 10.1 Mylotarg
    • 10.1.1 Availability & Patent Insight
    • 10.1.2 Pricing & Dosage Insight
  • 10.2 Adcetris
    • 10.2.1 Availability & Patent Insight
    • 10.2.2 Pricing & Dosage Insight
  • 10.3 Kadcyla
    • 10.3.1 Availability & Patent Insight
    • 10.3.2 Pricing & Dosage Insight
  • 10.4 Besponsa
    • 10.4.1 Availability & Patent Insight
    • 10.4.2 Pricing & Dosage Insight
  • 10.5 Lumoxiti (Market Withdrawal In 2023)
    • 10.5.1 Availability & Patent Insight
    • 10.5.2 Pricing & Dosage Insight
  • 10.6 Polivy
    • 10.6.1 Availability & Patent Insight
    • 10.6.2 Pricing & Dosage Insight
  • 10.7 Padcev
    • 10.7.1 Availability & Patent Insight
    • 10.7.2 Pricing & Dosage Insight
  • 10.8 Enhertu
    • 10.8.1 Availability & Patent Insight
    • 10.8.2 Pricing & Dosage Insight
  • 10.9 Trodelvy
    • 10.9.1 Availability & Patent Insight
    • 10.9.2 Pricing & Dosage Insight
  • 10.10 Blenrep (Partial Market Withdrawal In 2023)
    • 10.10.1 Availability & Patent Insight
    • 10.10.2 Pricing & Dosage Insight
  • 10.11 Zynlonta
    • 10.11.1 Availability & Patent Insight
    • 10.11.2 Pricing & Dosage Insight
  • 10.12 Tivdak
    • 10.12.1 Availability & Patent Insight
    • 10.12.2 Pricing & Dosage Insight
  • 10.13 Elahere
    • 10.13.1 Availability & Patent Insight
    • 10.13.2 Pricing & Dosage Insight
  • 10.14 Ujvira
    • 10.14.1 Availability & Patent Insight
    • 10.14.2 Pricing & Dosage Insight
  • 10.15 Akalux
    • 10.15.1 Availability & Patent Insight
    • 10.15.2 Pricing & Dosage Insight
  • 10.16 Aidixi
    • 10.16.1 Availability Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights & Forecast 2028

  • 11.1 Adcetris
  • 11.2 Padcev
  • 11.3 Tivdak
  • 11.4 Polivy
  • 11.5 Kadcyla
  • 11.6 Besponsa
  • 11.7 Enhertu
  • 11.8 Trodelvy
  • 11.9 Zynlonta
  • 11.10 Elahere
  • 11.11 Blenrep

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

  • 12.1 Research
  • 12.2 Preclinical
  • 12.3 Phase I
  • 12.4 Phase I/II
  • 12.5 Phase II
  • 12.6 Phase II/III
  • 12.7 Phase III
  • 12.8 Preregistration

13. Marketed Cancer Antibody Drug Conjugates Clinical Insight By Company, Country & Indication

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

  • 15.1 Key Market Growth Drivers
  • 15.2 Challenges For Market Growth

16. Competitive Landscape

  • 16.1 Biocytogen
  • 16.2 Bristol Myers Squibb
  • 16.3 Eli Lilly
  • 16.4 Innovent Biologics
  • 16.5 Merck
  • 16.6 Pfizer
  • 16.7 Affinity Biopharma
  • 16.8 Biokin
  • 16.9 Synaffix
  • 16.10 ADC Therapeutics
  • 16.11 AstraZeneca
  • 16.12 Daiichi Sankyo
  • 16.13 Duality Biologics
  • 16.14 Immunogen
  • 16.15 LigaChem Biosciences